Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-04-30

FDA Approved: OZEMPIC — Supplemental Application (Novo Nordisk)

View source ↗

Summary

The FDA approves a supplemental application for OZEMPIC to support the oral semaglutide formulation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OZEMPIC (semaglutide)

Snippet

SUPPL AP for OZEMPIC (ORAL SEMAGLUTIDE)